A few weeks ago, on November 15, I reported on the public meeting held by the FDA to elicit input on the idea that drugs might have a new class beyond prescription and over-the-counter, called behind-the-counter, dispensed and, in essence, prescribed by a pharmacist.
Needless to say, the matter is controversial, especially between physician groups and pharmacist organizations. At the time of the meeting and in accompanying public notices, the FDA stated that the public comment period by which the public could enter comments into the docket would end yesterday, November 28. Yesterday the FDA announced that, in fact, the true deadline was December 17. Therefore, for those interested in providing comment, you have a few more weeks. You can submit comments by going to the dockets page.